Literature DB >> 29621440

Fairness in Manufacturing Cellular Therapies.

Amritava Das1, Krishanu Saha1, Pilar N Ossorio2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29621440      PMCID： PMC6548452          DOI： 10.1080/15265161.2018.1445792

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN： 1526-5161            Impact factor:   11.229


× No keyword cloud information.
  6 in total

1.  Ethical Guidance for Selecting Clinical Trials to Receive Limited Space in an Immunotherapy Production Facility.

Authors:  Nancy S Jecker; Aaron G Wightman; Abby R Rosenberg; Douglas S Diekema
Journal:  Am J Bioeth       Date:  2018-04       Impact factor: 11.229

Review 2.  A guide to manufacturing CAR T cell therapies.

Authors:  Philipp Vormittag; Rebecca Gunn; Sara Ghorashian; Farlan S Veraitch
Journal:  Curr Opin Biotechnol       Date:  2018-02-18       Impact factor: 9.740

3.  T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Authors:  Marcela V Maus; Andrew R Haas; Gregory L Beatty; Steven M Albelda; Bruce L Levine; Xiaojun Liu; Yangbing Zhao; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

Review 4.  A systematic review of models to predict recruitment to multicentre clinical trials.

Authors:  Katharine D Barnard; Louise Dent; Andrew Cook
Journal:  BMC Med Res Methodol       Date:  2010-07-06       Impact factor: 4.615

Review 5.  Global Manufacturing of CAR T Cell Therapy.

Authors:  Bruce L Levine; James Miskin; Keith Wonnacott; Christopher Keir
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-31       Impact factor: 6.698

Review 6.  Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts.

Authors:  Jessica Hartmann; Martina Schüßler-Lenz; Attilio Bondanza; Christian J Buchholz
Journal:  EMBO Mol Med       Date:  2017-09       Impact factor: 12.137
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.